
|Articles|October 1, 2012
Unapproved neurotoxins abound, dermatologist warns
The approval of the newest botulinum toxin product available in the United States underscores the value of the Food and Drug Administration drug approval process and the importance of using branded products, says Mich?l H. Gold, M.D.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
KT-621 in Atopic Dermatitis: What Early EASI and Pruritus Data Show
2
Once-Daily Zasocitinib Rivals Injectable Biologics for Skin Clearance, Phase 3 Data Show
3
Social Media Mythbusters: Skin Cycling
4
Filling the HS Treatment Gap: Ruxolitinib Targets Early-Stage Disease
5














